Skip to main content
Affluent Medical logo

Affluent Medical — Investor Relations & Filings

Ticker · AFME ISIN · FR0013333077 LEI · 969500N30CO4B5N2GN67 PA Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2026-01-05 Share Issue/Capital Cha…
Country FR France
Listing PA AFME

About Affluent Medical

https://www.affluentmedical.com

Affluent Medical is a clinical-stage medical technology company that develops innovative, minimally invasive implants designed to restore essential physiological functions. The company's activities are concentrated in two primary therapeutic areas: structural heart disease and urology. It specifically addresses severe mitral valve insufficiency and urinary incontinence. The product pipeline, currently in clinical development, features three key devices: Kalios™, an adjustable annuloplasty ring for mitral valve repair; Epygon™, a biomimetic mitral valve for replacement procedures; and Artus™, an electronic artificial urinary sphincter for treating urinary incontinence. Affluent Medical's technologies are engineered to be adjustable and biomimetic, allowing for implantation via minimally invasive surgery and adaptation to both the patient's anatomy and the progression of their pathology.

Recent filings

Filing Released Lang Actions
Affluent Medical : Nombre dactions composant le capital social et nombre total de droits de vote au 30.11.25.
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory announcement from Affluent Medical regarding the total number of shares and voting rights as of November 30, 2025. This is a standard disclosure required by French financial regulations (AMF) regarding capital structure. While it relates to share capital, it is specifically a periodic disclosure of voting rights rather than a transaction in own shares (POS) or a new share issuance (SHA). Given the nature of the disclosure as a regulatory filing for transparency, it fits best under the RNS (Regulatory Filings) category.
2026-01-05 French
Affluent Medical announces upcoming acquisition of Caranx Medical and Artedrone, becoming Carvolix, pioneering cardiovascular therapies.
M&A Activity Classification · 100% confidence The document is a press release from Affluent Medical announcing the acquisition of two companies (Caranx Medical and Artedrone) to form a new entity, Carvolix. It details the financial terms of the acquisition, including share issuance and earn-out conditions, as well as a concomitant financing round of up to €30M. Since the document describes a merger and acquisition (M&A) transaction, it falls under the M&A Activity category.
2025-12-19 English
Affluent Medical annonce l’acquisition prochaine de Caranx Medical et Artedrone et devient Carvolix, pionnier des thérapies cardiovasculaires.
M&A Activity Classification · 100% confidence The document is a press release from Affluent Medical announcing the acquisition of two other companies (Caranx Medical and Artedrone) to form a new entity called Carvolix, along with a concurrent financing round. This is a classic M&A announcement detailing the transaction structure, financial terms, and strategic rationale. It fits the definition of M&A Activity (TAR) as it concerns merger proposals and corporate takeovers.
2025-12-19 French
Affluent Medical announces upcoming acquisition of Caranx Medical and Artedrone, becoming Carvolix, pioneering cardiovascular therapies.
M&A Activity Classification · 100% confidence The document is a press release announcing a strategic acquisition of two companies (Caranx Medical and Artedrone) by Affluent Medical to form a new entity, Carvolix. It details the transaction structure, financing, and future business strategy. This falls under M&A activity, which is classified as TAR.
2025-12-19 English
Affluent Medical : Nombre d’actions composant le capital social et nombre total de droits de vote au 30.09.25.
Share Issue/Capital Change Classification · 95% confidence The document is a formal notification from Affluent Medical regarding the total number of shares and voting rights, as required by Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. This type of disclosure is a standard regulatory requirement for listed companies to inform the market about their capital structure and voting rights, which falls under the category of general regulatory filings.
2025-11-05 French
Affluent Medical : Nombre d’actions composant le capital social et nombre total de droits de vote au 31.10.25.
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a regulatory disclosure required by Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. It provides the total number of shares and voting rights for Affluent Medical as of October 31, 2025. This type of disclosure is a standard regulatory filing regarding capital structure and voting rights, which does not fit into specific categories like M&A, dividends, or director dealings, making 'RNS' (Regulatory Filings) the most appropriate classification.
2025-11-05 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.